Patents by Inventor Gert Bolt

Gert Bolt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180179262
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: February 8, 2018
    Publication date: June 28, 2018
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Hjortnaes Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen
  • Patent number: 9982033
    Abstract: The invention relates to a method for the production of a Factor VIII polypeptide, the method comprising the steps of a) culturing a mammalian cell expressing a Factor VIII polypeptide under conditions for expression of said Factor VIII polypeptide, said culturing conditions involving a cell culture medium comprising a C2-domain ligand, and b) isolating the expressed Factor VIII polypeptide from the mammalian cell by suitable means.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: May 29, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Laust Bruun Johnsen, Ida Hilden, Gert Bolt, Thomas Dock Steenstrup
  • Publication number: 20170020992
    Abstract: The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group.
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Inventors: Gert Bolt, Bernd Peschke, Mikael Kofod-Hansen, Jens Buchardt, Henning Ralf Stennicke, Henrik Oestergaard, Marianne Kjalke, Eva H. Norling Olsen, Jens Jacob Hansen, Magali Zundel
  • Publication number: 20170015729
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules fused to a polypeptide such as e.g. an antibody binding protein or a Fc domain.
    Type: Application
    Filed: October 4, 2016
    Publication date: January 19, 2017
    Applicant: Novo Nordisk A/S
    Inventors: Gert Bolt, Kristian Kjaergaard, Peder Lisby Noerby, Ole Hvilsted Olsen
  • Patent number: 9493543
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules fused to a polypeptide such as e.g. an antibody binding protein or a Fc domain.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: November 15, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Gert Bolt, Kristian Kjaergaard, Peder Lisby Noerby, Ole Hvilsted Olsen
  • Publication number: 20160318991
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 3, 2016
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen
  • Publication number: 20160222086
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half-life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Application
    Filed: August 20, 2015
    Publication date: August 4, 2016
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn Defrees
  • Publication number: 20160207977
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Application
    Filed: June 10, 2014
    Publication date: July 21, 2016
    Inventors: Ole Hvilsted Olsen, Marianne Hjortnaes Kjalke, Maj Petersen, Lars Thim, Kirstine Roepstorff, Jens Jacob Hansen, Jesper Haaning, Frederik Rode, Ditte Maria Karpf, Christian Rischel, Gert Bolt
  • Publication number: 20160120954
    Abstract: The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 5, 2016
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Peder L. Noerby, Jens J. Hansen
  • Patent number: 9150848
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: October 6, 2015
    Assignee: Novo Nordisk A/s
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
  • Patent number: 9125890
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: September 8, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen, Christian Rischel
  • Publication number: 20150080309
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 19, 2015
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens J. Hansen
  • Publication number: 20150045303
    Abstract: The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 12, 2015
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Peder L. Noerby, Jens J. Hansen
  • Patent number: 8871714
    Abstract: The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: October 28, 2014
    Assignee: Novo Nordisk Health Care AG
    Inventors: Gert Bolt, Claus Kristensen
  • Publication number: 20140242057
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Application
    Filed: May 8, 2014
    Publication date: August 28, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
  • Publication number: 20140018297
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Application
    Filed: June 12, 2013
    Publication date: January 16, 2014
    Inventors: Gert Bolt, Ditte Marie Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen, Christian Rischel
  • Patent number: 8536126
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: September 17, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
  • Publication number: 20130189239
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Application
    Filed: February 26, 2009
    Publication date: July 25, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn Defrees
  • Publication number: 20130040889
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules fused to a polypeptide such as e.g. an antibody binding protein or a Fc domain.
    Type: Application
    Filed: February 10, 2011
    Publication date: February 14, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Gert Bolt, Kristian Kjaergaard, Peder Lisby Noerby
  • Publication number: 20110137011
    Abstract: The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia.
    Type: Application
    Filed: April 21, 2009
    Publication date: June 9, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Gert Bolt, Claus Kristensen